Differences in reserpine-induced striatal dopamine output and content between female and male mice: Implications for sex differences in vesicular monoamine transporter 2 function

Neuroscience

Volumn 154, Issue 4, 2008, Pages 1488-1496

  Dluzen, D E ^a   Bhatt, S ^a   McDermott, J L ^a  

^a Northeastern Ohio Medical University   (United States)

Author keywords

dopamine transporter; drug addiction; gender differences; nigrostriatal; Parkinson's disease

Indexed keywords

DOPAMINE; ESTROGEN; RESERPINE; STEROID HORMONE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ARTICLE; CORPUS STRIATUM; DRUG DEPENDENCE; FEMALE; GONADECTOMY; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; FEMALE; MALE; MICE; ORCHIECTOMY; OVARIECTOMY; RESERPINE; SEX CHARACTERISTICS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 45949102483     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.04.051     Document Type: Article

References (56)

1. Attali G., Weizman A., Gil-Ad I., and Rehavi M. Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters. Brain Res 756 (1997) 153-159
2. Bhatt S.D., and Dluzen D.E. Dopamine transporter function differences between male and female CD-1 mice. Brain Res 1035 (2005) 188-195
3. Bosse R., Rivest R., and Di Paolo T. Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Brain Res Mol Brain Res 46 (1997) 343-346
4. Brooks W.J., Jarvis M.F., and Wagner G.C. Influence of sex, age and strain of MPTP-induced neurotoxicity. Res Commun Subst Abuse 10 (1989) 181-184
5. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., Colebrooke R.E., Di Monte D.A., Emson P.C., and Miller G.W. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27 (2007) 8138-8148
6. Clarke P.B., and Reuben M. Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter. Br J Pharmacol 114 (1995) 315-322
7. Colebrooke R.E., Humby T., Lynch P.J., McGowan D.P., Xia J., and Emson P.C. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur J Neurosci 24 (2006) 2622-2630
8. Czlonkowska A., Ciesielska A., Gromadzka G., and Kurkowska-Jastrzebska I. Gender differences in neurological disease: role of estrogens and cytokines. Endocrine 29 (2006) 243-256
9. Daniels A.J., and Reinhard Jr. J.F. Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J Biol Chem 263 (1988) 5034-5036
10. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 5 (1994) 27-41
11. Dluzen D.E., Disshon K.A., and McDermott J.L. Estrogen as a modulator of striatal dopaminergic neurotoxicity. In: Marwah J., and Tietelbaum H. (Eds). Recent advances in neurological disorders (1998), Prominent Press, Scottsdale, AZ 149-192
12. Dluzen D.E., and Liu B. Gender differences in methamphetamine use and responses. Gend Med 5 (2008) 24-53
13. Dluzen D.E., Tweed C., Anderson L.I., and Laping N.J. Gender differences in methamphetamine-induced mRNA associated with neurodegeneration in the mouse nigrostriatal dopaminergic system. Neuroendocrinology 77 (2003) 232-238
14. Erickson J.D., Eiden L.E., and Hoffman B.J. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A 89 (1992) 10993-10997
15. Freyaldenhoven T.E., Cadet J.L., and Ali S.F. The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent. Brain Res 735 (1996) 232-238
16. Fumagalli F., Jones S., Bosse R., Jaber M., Giros B., Missale C., Wightman R.M., and Caron M.G. Inactivation of the dopamine transporter reveals essential roles of dopamine in the control of locomotion, psychostimulant response and pituitary function. Adv Pharmacol 42 (1998) 179-182
17. Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69 (1997) 1322-1325
18. Glatt C.E., Wahner A.D., White D.J., Ruiz-Linares A., and Ritz B. Gain of function haplotypes in the vesicular monoamine transporter are protective for Parkinson's disease in women. Hum Mol Genet 15 (2006) 299-305
19. Hall J.N., and Broderick P.M. Community networks for response to abuse outbreaks of methamphetamine and its analogs. NIDA Res Monogr 115 (1991) 109-120
20. Iversen L.L. Uptake process of biogenic amines. In: Iversen L.L., Iversen S.D., and Snyder S.H. (Eds). Handbook of psychopharmacology (1975), Plenum Press, New York 381-442
21. Jaber M., Jones S., Giros B., and Caron M.G. The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 12 (1997) 629-633
22. Ji J., and Dluzen D.E. Sex differences in striatal dopaminergic function within heterozygous mutant dopamine transporter knock-out mice. J Neural Transm (2008) doi: 10.1007/s00702-007-0017-0
23. +-evoked striatal dopamine output from superfused striatal tissue fragments of reserpine-treated CD-1 mice. J Neuroendocrinol 19 (2007) 725-731
24. Lavalaye J., Booji J., Reneman L., Harbraken J.B., and von Royen E.A. Effect of age and gender on dopamine transporter imaging with [123I] FP-CIT SPET in healthy volunteers. Eur J Nucl Med 27 (2000) 867-869
25. Le Saux M., and Di Paolo T. Influence of estrogenic compounds on monoamine transporter in rat striatum. J Neuroendocrinol 18 (2006) 25-32
26. McArthur S., Murray H.E., Dhankot A., Dexter D.T., and Gillies G.E. Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormones effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition. J Neurochem 100 (2007) 678-692
27. Miller D.B., Ali S.F., O'Callaghan J.P., and Laws S.C. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann N Y Acad Sci 844 (1998) 153-165
28. Miller G.W., Gainetdinov R.R., Levey A.I., and Caron M.G. Dopamine transporters and neuronal injury. Trends Pharmacol Sci 20 (1999) 424-429
29. Morissette M., Biron D., and Di Paolo T. Effect of estradiol and progesterone on rat striatal dopamine uptake sites. Brain Res Bull 25 (1990) 419-422
30. Morissette M., and Di Paolo T. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. J Neurochem 60 (1993) 1876-1883
31. Morissette M., and Di Paolo T. Sex and estrous cycle variations of striatal dopamine uptake sites. Neuroendocrinology 58 (1993) 16-22
32. Moriyama Y., Amakatsu K., and Futai M. Uptake of the neurotoxin, 4-methylphenylpyridinium, into chromaffin granules and synaptic vesicles: a proton gradient drives its uptake through monoamine transporter. Arch Biochem Biophys 305 (1993) 271-277
33. Mozley L.H., Gur R.C., Mozley P.D., and Gur R.E. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 158 (2001) 1492-1499
34. Murray H.E., Pillai A.V., McArthur S.R., Razxi N., Dalta K.P., Dexter D.T., and Gillies G.E. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 116 (2003) 213-222
35. Rehavi M., Goldin M., Roz N., and Weizman A. Regulation of rat vesicle monoamine transporter by chronic treatment with ovarian hormones. Brain Res Mol Brain Res 57 (1998) 31-37
36. Reinhard Jr. J.F., Diliberto Jr. E.J., Viveros O.H., and Daniels A.J. Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci U S A 84 (1987) 8160-8164
37. Ricaurte G.A., Langston J.W., DeLanney L.E., Irwin I., and Brooks J.D. Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett 59 (1985) 259-264
38. Rivest R., Flardeau P., and Di Paolo T. Brain dopamine transporter: gender differences and effects of chronic haloperidol. Brain Res 692 (1995) 269-272
39. Sanghera M.K., Manaye K., McMahon A., Sonsalla P.K., and German D.C. Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP. Neuroreport 8 (1997) 3327-3331
40. Shulman L.M. Gender differences in Parkinson's disease. Gend Med 4 (2007) 8-18
41. Shulman L.M., and Bhat V. Gender disparities in Parkinson's disease. Expert Rev Neurother 60 (2006) 407-416
42. Staley J.K., Krishnan-Sarin S., Zoghbi S., Tamagnan G., Fujita M., Seibyl J.P., Maciejewski P.K., O'Malley S., and Innis R.B. Sex differences in [123I];B-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 41 (2001) 275-284
43. Uhl G.R. Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 43 (1998) 555-560
44. Unzeta M., Baron S., Perez V., Ambrosio S., and Mahy N. Sex-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine treatment may be related to differences in monoamine oxidase B. Neurosci Lett 176 (1994) 235-238
45. Vaccari A., and Biassoni R. Gonadal influences on the inhibition of monoamine oxidase type B activity. J Neurosci Res 8 (1982) 13-19
46. van der Elst M.C.J., Wunderink Y.S., Ellenbrook B.A., and Cools A.R. Differences in the cellular mechanism underlying the effects of amphetamine on prepulse inhibition in apomorphine-susceptible and apomorphine-unsusceptible rats. Psychopharmacology 190 (2007) 93-102
47. Verheij M.M.M., and Cools A.R. Differential contribution of storage pools to the extracellular amount of accumbal dopamine in high and low responders to novelty: effects of reserpine. J Neurochem 100 (2007) 810-821
48. Vijayalakshmi V., Lele J.V., and Daginawala H.F. Effect of reserpine on the monoamine oxidase (MAO) activity in rat liver and brain. Biochem Pharmacol 27 (1978) 1985-1986
49. Volz T.J., Farnsworth S.J., King J.L., Riddle E.L., Hanson G.R., and Fleckenstein A.E. Methylphenidate administration alters vesicular monoamine transporters-2 function in cytoplasmic and membrane-associated vesicles. J Pharmacol Exp Ther 323 (2007) 738-745
50. Volz T.J., Hanson G.R., and Fleckenstein A.E. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficiencies. J Neurochem 101 (2007) 883-888
51. Wagner G.C., Tekirian T.L., and Cheo C.T. Sexual differences in sensitivity to methamphetamine toxicity. J Neural Transm 93 (1993) 67-70
52. Walker Q.D., Rooney M.B., Wightman R.M., and Kuhn C.M. Dopamine release and uptake are greater in female than male striatum as measured by fast cyclic voltammetry. Neuroscience 95 (2000) 1061-1070
53. Yavich L., and MacDonald E. Dopamine release from pharmacologically distinct storage pools in rat striatum following stimulation at frequency of neuronal bursting. Brain Res 870 (2000) 73-79
54. Youngster S.K., Nicklas W.J., and Heikkila R.E. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs. J Pharmacol Exp Ther 249 (1989) 829-835
55. Yu L., and Liao P.C. Estrogen and progesterone distinctly modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. J Neural Transm 107 (2000) 1139-1147
56. Yu Y.L., and Wagner G.C. Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity. J Neural Transm Park Dis Dement Sect 8 (1994) 215-221